Möchten Sie immer auf dem neuesten Stand bleiben?

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market...

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indicationsCompany plans to meet with FDA to align on path forward for...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second...

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...

DUBAI, United Arab Emirates, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a decentralized finance project developing a non-custodial lending and borrowing protocol, has entered Presale...

DUBAI, United Arab Emirates, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a new crypto project focused on decentralized lending, has shared updates on its product development as its...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...